Inclusion Criteria:

• Able to read consent form and give informed consent.
• At least 15 years old.
• Histologically confirmed non-lymphoid hematological malignancy.
• Recipient of T cell depleted bone marrow (BM) or peripheral blood stem cell (PBSC) transplant from a 6/6 HLA (A, B, DR by intermediate resolution) identical related or unrelated donor after myeloablative conditioning.
• Received TCD HCT containing < 1x105 CD3+ T cells/kg of recipient.

• Patient included in at least one of the following categories:

  • AML in 2nd or greater complete remission.
  • High-risk AML (high-risk cytogenetics, undifferentiated leukemia, secondary AML, antecedent MDS) in 1st remission.
  • CML in 2nd or greater chronic phase, 2nd or greater accelerated phase.
  • MDS intermediate or high risk by IPSS criteria.
• History of opportunistic infection (CMV viremia requiring anti-viral therapy, PCP pneumonia, mycobacterial infection, herpes zoster, viral respiratory infection (influenza, RSV, para-influenza), etc.
• CD4+ T cell count < 100 at 6 months post-transplant.
• At high risk for opportunistic infection (e.g., history of treated invasive fungal infection prior to the transplantation, positive CMV serology in patient, or positive toxoplasmosis serology in donor and patient, etc.).
• 60 - 210 days post transplant.
• In remission at the time of initiation of CYT107.
• Documented engraftment with sustained neutrophil counts of at least 1000/mcl and untransfused platelet counts > 20 000/mcl for 3 consecutive lab values (the last one tested <10 days before initiation of treatment) on 3 different days prior to treatment. Patients who have engrafted but require G-CSF for myelosuppressive antibiotics or antiviral medications are eligible if they require G-CSF no more than twice weekly and their ANC remains >1000/mcl.
• KPS > 60%.

• Adequate organ function:

  • Cardiac: No evidence of change in cardiac function by history, exam and/or EKG post-HCT.
  • Pulmonary: Absence of dyspnea or hypoxia (< 90% of saturation by pulse oxymetry on room air).
  • Hepatic: Bilirubin <= 1.5 X ULN, AST (SGOT) and /or ALT (SGPT) <= 2.5 X ULN. PT/PTT < 1.5 X ULN.
  • Renal: Calculated Creatinine clearance > 60 mL/min/1.73 m2. [Note: all transplant patients had an ejection fraction of > 40% on their pre-transplant echocardiogram and a DLCO > 50% of predicted (corrected for hemoglobin)]

Exclusion Criteria:

• No evidence or history of acute GVHD or of chronic GVHD.
• No recurrent leukemia post HCT.
• No active uncontrolled viral, bacterial or fungal infection.
• No documented HIV-1 or -2, HBV or HCV infection at any time before or after transplant (a positive hepatitis B serology indicative of a previous immunization is not an exclusion criteria).
• Not be receiving systemic corticosteroid, anti-mitotic agent or other immunosuppressive treatment.
• Not receiving Growth Hormone or gonadotropin agonists/ antagonists.
• Not receiving any cytokine support other than G-CSF post-HCT.
• Not receiving concurrent treatment with another investigational drug and/or biological agent.
• Not receiving anticoagulant therapy.
• No uncontrolled hypertension.
• No history of lymphoid malignancy (e.g. Hodgkin disease, non Hodgkin lymphoma, Acute Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia) or acute biphenotypic leukemia.
• No peripheral lymphadenopathy (any lymph node > 1 cm).
• No history of EBV associated lymphoproliferation.
• No EBV viremia equal to or greater than 500 copies EBV DNA/mL of blood by quantitative PCR.
• No history of autoimmune disease nor a HCT donor with a history of an autoimmune disease.
• Fertile patients must use effective birth control. Not pregnant or nursing. Negative pregnancy test within 2 weeks of study treatment.
• QTc prolongation (QTc > 470 ms) or prior history of significant arrhythmia or ECG abnormalities.
• No active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
• Any past or current psychiatric illness that, in the opinion of the investigator, would interfere with adherence to study requirements or the ability and willingness to give written informed consent.